Development process of the Nanotaxi®-based novel biotherapeutics

Target ID/Gene design

Identification of protein of therapeutic or antigenic interest

Design and optimization of the corresponding nucleic acid (DNA or mRNA) coding the proteins

Nucleic Acids Production

Production and quality control of plasmid DNA or mRNA encoding the protein of interest

Nanotaxi® production

Optimized In-Cell-Art proprietary Nanotaxi® produced by state of the art organic chemistry

Industrial synthesis of Nanotaxi® outsourced to GMP-approved CMO

Full package of chemical and physico-chemical characterization

Nanotaxi®/Nucleic Acids production

Supramolecular assemblies between Nanotaxi®/Nucleic acids produced by self assembling process. No use of specific mixing devices

Industrial fill and finishing of Nanotaxi®/Nucleic Acids outsourced to GMP-approved CMO

POC, animal experiment

Optimization of the protein of therapeutic or antigenic interest in the chosen animal specie including Non Human Primate

Optimization of the physiological activity (therapeutic or vaccination) in the chosen animal specie after Nanotaxi®/Nucleic acids administration

GLP tox

Safety profile of Nanotaxi® and Nanotaxi®/Nucleic acids assessed in safety toxicological studies

Injection of Nanotaxi® using conventional administration methods

Clinical studies

Clinical trials to assess safety and efficiency in humans


Main projects of research & development

  • Hepavac

    • Preclinical development (efficiency, toxicity, bio-distribution) of a new immunotherapy vector composed of Nanotaxi® and plasmid DNA coding an anti- tumor antigen specific to hepatic cancer

    €3.8m over 3 years (2010-2013)

  • RNArmorvax

    • Objective is to develop and validate a new universal vaccine technology platform based on mRNA with substantial advantages over existing technologies
    • Test this approach in prophylactic and therapeutic vaccines for infectious diseases

    $33.1m over 4 years (2011-2015)


    • Accelerate the development of effective immunotherapy solutions against emerging health risk viruses with high pandemic potential (e.g. SARS, Ebola and Avian Flu H5N1)
    • Prepare production and commercialization steps 

    €20m over 5 years (2012-2017)


    • Develop a new strategy of immunotherapy by producing with Nanotaxi/mRNA, antibodies involved in the control of immune reaction against tumor cells 
    • Evaluate the synergistic effects with the Hepavac vaccine to treat hepatocellular carcinoma


A strong network of partners at each step of the value chain


In-Cell-Art is considered a reference in novel biotherapeutics and has attracted considerable attention nationally and internationally for its technological breakthroughs :

  • The company was co-financed by the US Defense Advanced Research Projects Agency (DARPA) for the four-year RNArmorvax project with Sanofi-Pasteur and CureVac with a total budget of US$33.1 million.

In-Cell-Art is also a leading and recognized member of its cluster and has been awarded several prizes and subsidies by local and national committees such as Bpifrance and the Pays de la Loire Region which is among the leading regions in France in terms of economic development and a seed bed for biotechnology start-ups.

Academic Institutions, Companies and Distributors

In-Cell-Art has long relationships with various world-renowed academic institutions, industrial companies and international distributors for the development and commercialization of novel classes of vaccines or therapeutic products.


In-Cell-Art Corporate

February 2017

Nanotaxi® publications

April 2017